Status:
UNKNOWN
Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial
Lead Sponsor:
Medical University Innsbruck
Conditions:
Anogenital Human Papillomavirus Infection
Condyloma Anal
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
AdAM is a prospective, randomized, controlled, double-blinded, monocentric trial in patients receiving surgical therapy due to anal HPV infection. Aim of the study is to evaluate efficacy of combinat...
Eligibility Criteria
Inclusion
- Ability to understand and willingness to sign and date a written consent document
- Male and female patients \>= 18 years of age
- Negative urine/serum pregnancy test
- Indication for surgical therapy of anal HPV lesions
Exclusion
- Participation in another clinical study with experimental therapy
- Diagnosis and therapy of HPV associated lesions in the last 12 months
- Known intolerance of hypersensitivity to Imiquimod
- Women who are pregnant of lactating
Key Trial Info
Start Date :
November 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 15 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03289260
Start Date
November 15 2021
End Date
November 15 2024
Last Update
September 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Visceral-, Transplant- and Thoracic Surgery
Innsbruck, Tyrol, Austria, 6020